Clinical evaluation study of Beta-glucan assay

Clinical evaluation study of Beta-glucan assay - Evaluation study of an adjunctive diagnostic assay for invasive fungal infections

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050121

Enrollment

900

Registered

2023-02-01

Start date

2023-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive fungal infections

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with suspected deep-seated mycosis and Beta-glucan measurement is performed

Exclusion criteria

Exclusion criteria: Patients whose consent cannot be obtained or who are deemed inappropriate by the physician in charge

Design outcomes

Primary

Measure	Time frame
Primary endpoint: Diagnostic performance of Beta-glucan assay reagents We will evaluate the application performance of each reagent by measuring specimens suspected of having deep-seated mycosis with each company's Beta-glucan assay reagent and comparing the results with the diagnostic results in a retrospective manner.	—

Secondary

Measure	Time frame
Secondary endpoint: Correlation of Beta-glucan assay reagents from various companies	—

Countries

Japan

Contacts

Public ContactWataru Shibata

Osaka Metropolitan University Graduate School of Medicine Department of Infection Control Science

shibata.wataru@omu.ac.jp06-6645-3784

Outcome results